ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiaze-based CD25-targeting antibody drug conjugate, in a phase 1 study of replased/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma Meeting Abstract
| Authors: | Collins, G. P.; Horwitz, S. M.; Davies, A.; Karnad, A.; Samaniego, F.; Spira, A. I.; Fields, P. A.; Menne, T.; Boni, J.; Cruz, H.; Feingold, J.; He, S.; Wuerthner, J.; Hamadani, M. |
| Abstract Title: | ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiaze-based CD25-targeting antibody drug conjugate, in a phase 1 study of replased/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837605034 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-115986 |
| Notes: | Meeting Abstract: 1658 -- Source: Wos |
